sirolimus-eluting coronary stent

sirolimus-eluting coronary stent

Cardiology A coronary artery stent graft which has sirolimus, an imunosuppressive and antimitotic agent incorporated into its matrix, which significantly ↓ restenosis of stents.
See RAVEL.
Mentioned in ?
References in periodicals archive ?
The MiStent Sirolimus-Eluting Coronary Stent System is designed to optimize healing in patients with coronary artery disease.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, has announced at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions".
WATERLOO, Belgium, September 30, 2010 /PRNewswire/ -- Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott's XIENCE V (R) Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months.
market since 2003 and 2004 are the Cypher sirolimus-eluting coronary stent manufactured by Cordis Corporation, and the Taxus Express paclitaxel-eluting coronary stent system, respectively.
Sales and marketing resources of both companies will join forces to focus on promoting the CYPHER Sirolimus-eluting Coronary Stent in the United States, with an option to pursue a similar arrangement in Japan in the future.
Additionally, Cardionovum expects to launch before year-end a next-generation Sirolimus-eluting coronary stent system--PROLIMUS([R]) Biograde, whose design combines proven pro-healing features to promote early re-endothelialization.
In its separate news release today, Cordis announced the discontinuation of its clinical development program for the NEVO(TM) Sirolimus-Eluting Coronary Stent, cessation of the manufacture of CYPHER and CYPHER SELECT Plus Sirolimus-Eluting Coronary Stents by the end of 2011, and other plans related to its cardiovascular business.
The Publication of 10-Year Follow-Up Test Results on the First CYPHER(R) Sirolimus-Eluting Coronary Stent Patient Reveal the Stent's Outstanding Efficacy and Safety
The RAVEL study was sponsored by Cordis, a division of Johnson and Johnson, which markets the sirolimus-eluting coronary stent (Cypher).
They are designed to support demand for the current CYPHER(R) family of drug-eluting stents, including the CYPHER(R) Sirolimus-eluting Coronary Stent and the CYPHER SELECT(TM) Plus Sirolimus-eluting Coronary Stent, which has recently received the CE mark.
Cardionovum GmbH announced today that it expects to launch in Europe in Q4 2012 a next-generation Sirolimus-eluting coronary stent system--PROLIMUS Biograde--which is designed to optimize long-term patient results.